国产精品igao视频网网址不卡日韩,亚洲综合在线电影,亚洲婷婷丁香,黄色在线网站噜噜噜

  特發性肺纖維化 (idiopathic pulmonary fibrosis, IPF)，是進行性的間質性肺病并伴有持續的肺功能損傷^[2]。目前全球約有500萬人患有IPF，平均中位生存期為3-5年^[3]。然而迄今為止的上市藥物僅有吡非尼酮和尼達尼布，且為FDA弱推薦藥物，存在巨大未滿足的臨床需求^{[4, 5]}。

  2022年6月22日，上海交通大學藥學院章雪晴教授團隊聯合新澤西理工學院許曉陽教授團隊在Science Advances上發表了題為Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge的研究論文�；诳晌氲暮怂峒{米遞送載體，成功遞送小干擾RNA（siRNA）到達纖維化小鼠的肺部，實現肺纖維化的治療。上海交通大學柏欣博士為該論文的第一作者，上海交通大學藥學院為第一和通訊單位。

  參考文獻

  1, X. Bai, G. L. Zhao, Q. J. Chen, Z. Y. Li, M. Z. Gao, W. Ho, X. Y. Xu, X.-Q. Zhang, Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge. Sci. Adv. 8, eabn7162 (2022).

  2, R. Sharif, Overview of idiopathic pulmonary fibrosis (IPF) and evidence-based guidelines. Am. J. Manag. Care 23, S176–S182 (2017).

  3, E. Farrand, C. Iribarren, E. Vittinghoff, T. Levine-Hall, B. Ley, G. Minowada, H. R. Collard, Impact of idiopathic pulmonary fibrosis on longitudinal health-care utilization in a community-based cohort of patients. Chest 159, 219–227 (2021).

  4, G. Raghu, W. C. Johnson, D. Lockhart, Y. Mageto, Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label phase II study. Am. J. Respir. Crit. Care Med. 159, 1061–1069 (1999).

  5, M. Myllarniemi, R. Kaarteenaho, Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. Eur. Clin. Respir. J. 2 (2015).

  下載：Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge